Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CytomX Therapeutics, Inc. - Common Stock
(NQ:
CTMX
)
5.450
-1.300 (-19.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CytomX Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls
↗
Today 1:39 EDT
Analysts turned bullish, citing strong data and the drug's potential to expand into earlier treatment settings.
Via
Stocktwits
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
↗
March 16, 2026
Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.
Via
The Motley Fool
Topics
Stocks
Monday's session: most active stocks
↗
March 16, 2026
Via
Chartmill
These stocks are moving in today's session
↗
March 16, 2026
Via
Chartmill
CytomX Therapeutics Inc (NASDAQ:CTMX) Soars 56% on Positive Clinical Data Despite Earnings Miss
↗
March 16, 2026
Via
Chartmill
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Gapping stocks in Monday's session
↗
March 16, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 16, 2026
Via
Chartmill
Why CTMX Stock Is Soaring 54% Pre-Market Today?
↗
March 16, 2026
CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.
Via
Stocktwits
Which stocks are experiencing notable movement on Friday?
↗
January 16, 2026
Via
Chartmill
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen)
↗
January 15, 2026
Via
Chartmill
CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q3 2025 Earnings Miss, Stock Falls
↗
November 06, 2025
CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction.
Via
Chartmill
Topics
Earnings
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
October 21, 2025
Via
Benzinga
Why CytomX Therapeutics Stock Was Skyrocketing This Week
↗
September 26, 2025
One pundit believes the company might have a winning cancer drug in its pipeline.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
September 25, 2025
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.
Via
Benzinga
What's going on in today's after hours session
↗
September 25, 2025
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
↗
August 26, 2025
Via
Benzinga
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
August 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 12, 2025
Via
Benzinga
CytomX (CTMX) Q2 Revenue Drops 26%
↗
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS
↗
August 07, 2025
CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.
Via
Chartmill
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
↗
July 31, 2025
Via
Benzinga
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
↗
July 31, 2025
Via
Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
Via
Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech
↗
July 08, 2025
CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
Via
Chartmill
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
↗
May 28, 2025
Via
Benzinga
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
May 20, 2025
Via
Benzinga
This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
↗
May 15, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
